nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

08.07.2022 | Original Article

A quantitative in vivo imaging platform for tracking pathological tau depositions and resultant neuronal death in a mouse model

verfasst von: Taeko Kimura, Maiko Ono, Chie Seki, Kazuaki Sampei, Masafumi Shimojo, Kazunori Kawamura, Ming-Rong Zhang, Naruhiko Sahara, Yuhei Takado, Makoto Higuchi

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 13/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Depositions of tau fibrils are implicated in diverse neurodegenerative disorders, including Alzheimer’s disease, and precise assessments of tau pathologies and their impacts on neuronal survival are crucial for pursuing the neurodegenerative tau pathogenesis with and without potential therapies. We aimed to establish an in vivo imaging system to quantify tau accumulations with positron emission tomography (PET) and brain atrophy with volumetric MRI in rTg4510 transgenic mice modeling neurodegenerative tauopathies.

Methods

A total of 91 rTg4510 and non-transgenic control mice underwent PET with a tau radiotracer, ¹⁸F-PM-PBB3, and MRI at various ages (1.8–12.3 months). Using the cerebellum as reference, the radiotracer binding in target regions was estimated as standardized uptake value ratio (SUVR) and distribution volume ratio (DVR). Histopathological staining of brain sections derived from scanned animals was also conducted to investigate the imaging-neuropathology correlations.

Results

¹⁸F-PM-PBB3 SUVR at 40–60 min in the neocortex, hippocampus, and striatum of rTg4510 mice agreed with DVR, became significantly different from control values around 4–5 months of age, and progressively and negatively correlated with age and local volumes, respectively. Neocortical SUVR also correlated with the abundance of tau inclusions labeled with PM-PBB3 fluorescence, Gallyas-Braak silver impregnation, and anti-phospho-tau antibodies in postmortem assays. The in vivo and ex vivo ¹⁸F-PM-PBB3 binding was blocked by non-radioactive PM-PBB3. ¹⁸F-PM-PBB3 yielded a 1.6-fold greater dynamic range for tau imaging than its ancestor, ¹¹C-PBB3.

Conclusion

Our imaging platform has enabled the quantification of tau depositions and consequent neuronal loss and is potentially applicable to the evaluation of candidate anti-tau and neuroprotective drugs.

Nur mit Berechtigung zugänglich

Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci. 2001;24:1121–59. https://doi.org/10.1146/annurev.neuro.24.1.1121.CrossRefPubMed

Goedert M, Jakes R. Mutations causing neurodegenerative tauopathies. Biochem Biophys Acta. 2005;1739:240–50. https://doi.org/10.1016/j.bbadis.2004.08.007.PubMed

Myers A, McGonigle P. Overview of Transgenic mouse models for Alzheimer’s disease. Curr Protoc Neurosci. 2019;89:e81. https://doi.org/10.1002/cpns.81.CrossRefPubMed

Imbimbo BP, Ippati S, Watling M, Balducci C. A critical appraisal of tau-targeting therapies for primary and secondary tauopathies. Alzheimer’s Dement : J Alzheimer’s Assoc. 2021. https://doi.org/10.1002/alz.12453.

Panza F, Lozupone M, Seripa D, Daniele A, Watling M, Giannelli G, et al. Development of disease-modifying drugs for frontotemporal dementia spectrum disorders. Nat Rev Neurol. 2020;16:213–28. https://doi.org/10.1038/s41582-020-0330-x.CrossRefPubMed

Li C, Götz J. Tau-based therapies in neurodegeneration: opportunities and challenges. Nat Rev Drug Discovery. 2017;16:863–83. https://doi.org/10.1038/nrd.2017.155.CrossRefPubMed

Appleby BS, Nacopoulos D, Milano N, Zhong K, Cummings JL. A review: treatment of Alzheimer’s disease discovered in repurposed agents. Dement Geriatr Cogn Disord. 2013;35:1–22. https://doi.org/10.1159/000345791.CrossRefPubMed

Sato H, Takado Y, Toyoda S, Tsukamoto-Yasui M, Minatohara K, Takuwa H, et al. Neurodegenerative processes accelerated by protein malnutrition and decelerated by essential amino acids in a tauopathy mouse model. Sci Adv. 2021;7:eab5046. https://doi.org/10.1126/sciadv.abd5046.CrossRef

Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science (New York, NY). 2005;309:476–81. https://doi.org/10.1126/science.1113694.CrossRef

10.

Shelton LB, Baker JD, Zheng D, Sullivan LE, Solanki PK, Webster JM, et al. Hsp90 activator Aha1 drives production of pathological tau aggregates. Proc Natl Acad Sci USA. 2017;114:9707–12. https://doi.org/10.1073/pnas.1707039114.CrossRefPubMedPubMedCentral

11.

DeVos SL, Corjuc BT, Commins C, Dujardin S, Bannon RN, Corjuc D, et al. Tau reduction in the presence of amyloid-β prevents tau pathology and neuronal death in vivo. Brain : J Neurol. 2018;141:2194–212. https://doi.org/10.1093/brain/awy117.CrossRef

12.

Schaler AW, Runyan AM, Clelland CL, Sydney EJ, Fowler SL, Figueroa HY, et al. PAC1 receptor-mediated clearance of tau in postsynaptic compartments attenuates tau pathology in mouse brain. Sci Transl Med 2021;13. https://doi.org/10.1126/scitranslmed.aba7394

13.

Ishikawa A, Tokunaga M, Maeda J, Minamihisamatsu T, Shimojo M, Takuwa H, et al. In vivo visualization of tau accumulation, microglial activation, and brain atrophy in a mouse model of tauopathy rTg4510. J Alzheimer’s Dis : JAD. 2018;61:1037–52. https://doi.org/10.3233/jad-170509.CrossRef

14.

Higuchi M, Maeda J, Ji B, Maruyama M, Okauchi T, Tokunaga M, et al. In-vivo visualization of key molecular processes involved in Alzheimer’s disease pathogenesis: insights from neuroimaging research in humans and rodent models. Biochem Biophys Acta. 2010;1802:373–88. https://doi.org/10.1016/j.bbadis.2010.01.003.PubMed

15.

Colato E, Chiotis K, Ferreira D, Mazrina MS, Lemoine L, Mohanty R, et al. Assessment of tau pathology as measured by 18F-THK5317 and 18F-flortaucipir PET and their relation to brain atrophy and cognition in Alzheimer’s disease. J Alzheimer’s Dis : JAD. 2021;84:103–17. https://doi.org/10.3233/jad-210614.CrossRefPubMed

16.

Berron D, Vogel JW, Insel PS, Pereira JB, Xie L, Wisse LEM, et al. Early stages of tau pathology and its associations with functional connectivity, atrophy and memory. Brain : J Neurol. 2021;144:2771–83. https://doi.org/10.1093/brain/awab114.CrossRef

17.

Shimada H, Kitamura S, Shinotoh H, Endo H, Niwa F, Hirano S, et al. Association between Aβ and tau accumulations and their influence on clinical features in aging and Alzheimer’s disease spectrum brains: A [(11)C]PBB3-PET study. Alzheimer’s Dement (Amsterdam, Netherlands). 2017;6:11–20. https://doi.org/10.1016/j.dadm.2016.12.009.

18.

Tagai K, Ono M, Kubota M, Kitamura S, Takahata K, Seki C, et al. High-Contrast in vivo imaging of tau pathologies in Alzheimer’s and non-Alzheimer’s disease tauopathies. Neuron. 2021;109:42-58.e8. https://doi.org/10.1016/j.neuron.2020.09.042.CrossRefPubMed

19.

Fitzpatrick AWP, Falcon B, He S, Murzin AG, Murshudov G, Garringer HJ, et al. Cryo-EM structures of tau filaments from Alzheimer’s disease. Nature. 2017;547:185–90. https://doi.org/10.1038/nature23002.CrossRefPubMedPubMedCentral

20.

Zhang W, Tarutani A, Newell KL, Murzin AG, Matsubara T, Falcon B, et al. Novel tau filament fold in corticobasal degeneration. Nature. 2020;580:283–7. https://doi.org/10.1038/s41586-020-2043-0.CrossRefPubMedPubMedCentral

21.

Mishra SK, Yamaguchi Y, Higuchi M, Sahara N. Pick’s Tau fibril shows multiple distinct PET probe binding sites: insights from computational modelling. 2020;22. https://doi.org/10.3390/ijms22010349

22.

Brendel M, Jaworska A, Probst F, Overhoff F, Korzhova V, Lindner S, et al. Small-animal PET imaging of tau pathology with 18F-THK5117 in 2 transgenic mouse models. J Nucl Med : Off Publication, Soc Nucl Med. 2016;57:792–8. https://doi.org/10.2967/jnumed.115.163493.CrossRef

23.

Brendel M, Barthel H, van Eimeren T, Marek K, Beyer L, Song M, et al. Assessment of 18F-PI-2620 as a biomarker in progressive supranuclear palsy. JAMA Neurol. 2020;77:1408–19. https://doi.org/10.1001/jamaneurol.2020.2526.CrossRefPubMed

24.

Aguero C, Dhaynaut M, Normandin MD, Amaral AC, Guehl NJ, Neelamegam R, et al. Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue. Acta Neuropathol Commun. 2019;7:37. https://doi.org/10.1186/s40478-019-0686-6.CrossRefPubMedPubMedCentral

25.

Honer M, Gobbi L, Knust H, Kuwabara H, Muri D, Koerner M, et al. Preclinical evaluation of (18)F-RO6958948, (11)C-RO6931643, and (11)C-RO6924963 as novel PET radiotracers for imaging tau aggregates in Alzheimer disease. J Nucl Med : Off Publication, Soc Nucl Med. 2018;59:675–81. https://doi.org/10.2967/jnumed.117.196741.CrossRef

26.

Chaney AM, Lopez-Picon FR, Serrière S, Wang R, Bochicchio D, Webb SD, et al. Prodromal neuroinflammatory, cholinergic and metabolite dysfunction detected by PET and MRS in the TgF344-AD transgenic rat model of AD: a collaborative multi-modal study. Theranostics. 2021;11:6644–67. https://doi.org/10.7150/thno.56059.CrossRefPubMedPubMedCentral

27.

Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013;79:1094–108. https://doi.org/10.1016/j.neuron.2013.07.037.CrossRefPubMed

28.

Weng CC, Hsiao IT, Yang QF, Yao CH, Tai CY, Wu MF, et al. Characterization of (18)F-PM-PBB3 ((18)F-APN-1607) uptake in the rTg4510 mouse model of tauopathy. Molecules (Basel, Switzerland). 2020;25. https://doi.org/10.3390/molecules25071750.

29.

Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53:337–51. https://doi.org/10.1016/j.neuron.2007.01.010.CrossRefPubMed

30.

Congdon EE, Sigurdsson EM. Tau-targeting therapies for Alzheimer disease. Nat Rev Neurol. 2018;14:399–415. https://doi.org/10.1038/s41582-018-0013-z.CrossRefPubMedPubMedCentral

31.

Shoeibi A, Olfati N, Litvan I. Preclinical, phase I, and phase II investigational clinical trials for treatment of progressive supranuclear palsy. Expert Opin Investig Drugs. 2018;27:349–61. https://doi.org/10.1080/13543784.2018.1460356.CrossRefPubMed

32.

Ramsden M, Kotilinek L, Forster C, Paulson J, McGowan E, SantaCruz K, et al. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci : Off J Soc Neurosci. 2005;25:10637–47. https://doi.org/10.1523/jneurosci.3279-05.2005.CrossRef

33.

Sahara N, Ren Y, Ward S, Binder LI, Suhara T, Higuchi M. Tau oligomers as potential targets for early diagnosis of tauopathy. J Alzheimer’s Dis : JAD. 2014;40(Suppl 1):S91–6. https://doi.org/10.3233/jad-132429.CrossRef

34.

Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab : Off J Int Soc Cereb Blood Flow Metab. 1996;16:834–40. https://doi.org/10.1097/00004647-199609000-00008.CrossRef

35.

Lammertsma AA, Bench CJ, Hume SP, Osman S, Gunn K, Brooks DJ, et al. Comparison of methods for analysis of clinical [11C]raclopride studies. J Cereb Blood Flow Metab : Off J Int Soc Cereb Blood Flow Metab. 1996;16:42–52. https://doi.org/10.1097/00004647-199601000-00005.CrossRef

36.

Ono M, Sahara N, Kumata K, Ji B, Ni R, Koga S, et al. Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies. Brain : J Neurol. 2017;140:764–80. https://doi.org/10.1093/brain/aww339.

37.

Hashimoto H, Kawamura K, Igarashi N, Takei M, Fujishiro T, Aihara Y, et al. Radiosynthesis, photoisomerization, biodistribution, and metabolite analysis of 11C-PBB3 as a clinically useful PET probe for imaging of tau pathology. J Nucl Med : Off Publication, Soc Nucl Med. 2014;55:1532–8. https://doi.org/10.2967/jnumed.114.139550.CrossRef

38.

Ni R, Ji B, Ono M, Sahara N, Zhang MR, Aoki I, et al. Comparative in vitro and in vivo quantifications of pathologic tau deposits and their association with neurodegeneration in tauopathy mouse models. J Nucl Med: Off Publication, Soc Nucl Med. 2018;59:960–6. https://doi.org/10.2967/jnumed.117.201632.CrossRef

39.

Takeuchi H, Imamura K, Ji B, Tsukita K, Enami T, Takao K, et al. Nasal vaccine delivery attenuates brain pathology and cognitive impairment in tauopathy model mice. NPJ Vaccines. 2020;5:28. https://doi.org/10.1038/s41541-020-0172-y.CrossRefPubMedPubMedCentral

40.

Hashimoto H, Kawamura K, Takei M, Igarashi N, Fujishiro T, Shiomi S, et al. Identification of a major radiometabolite of [11C]PBB3. Nucl Med Biol. 2015;42:905–10. https://doi.org/10.1016/j.nucmedbio.2015.08.006.CrossRefPubMed

41.

Tai YC, Ruangma A, Rowland D, Siegel S, Newport DF, Chow PL, et al. Performance evaluation of the microPET focus: a third-generation microPET scanner dedicated to animal imaging. J Nucl Med : Off Publication, Soc Nucl Med. 2005;46:455–63.

42.

Kang HG, Tashima H, Nishikido F, Akamatsu G, Wakizaka H, Higuchi M, et al. Initial results of a mouse brain PET insert with a staggered 3-layer DOI detector. Phys Med Biol. 2021;66. https://doi.org/10.1088/1361-6560/ac311c

43.

Li L, Liu FT, Li M, Lu JY, Sun YM, Liang X, et al. Clinical utility of (18) F-APN-1607 tau PET imaging in patients with progressive supranuclear palsy. Mov Disord : Off J Mov Disord Soc. 2021;36:2314–23. https://doi.org/10.1002/mds.28672.CrossRef

44.

Pluta R, Ułamek-Kozioł M. Tau protein-targeted therapies in Alzheimer’s disease: current state and future perspectives. In: Huang X, editor. Alzheimer’s Disease: Drug Discovery. Brisbane (AU): Exon Publications Copyright: The Authors.; 2020

Titel: A quantitative in vivo imaging platform for tracking pathological tau depositions and resultant neuronal death in a mouse model
verfasst von: Taeko Kimura
Maiko Ono
Chie Seki
Kazuaki Sampei
Masafumi Shimojo
Kazunori Kawamura
Ming-Rong Zhang
Naruhiko Sahara
Yuhei Takado
Makoto Higuchi
Publikationsdatum: 08.07.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 13/2022
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-022-05898-3

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 13/2022

Hetero-bivalent agents targeting FAP and PSMA

Preclinical and first-in-human evaluation of 18F-labeled D-peptide antagonist for PD-L1 status imaging with PET

Promise of hypoxia-targeted tracers in metastatic lymph node imaging

Pilot study of a novel nanobody 68 Ga-NODAGA-SNA006 for instant PET imaging of CD8+ T cells

The value of FDG PET/CT imaging in outcome prediction and response assessment of lymphoma patients treated with immunotherapy: a meta-analysis and systematic review

PET/NIR-II fluorescence imaging and image-guided surgery of glioblastoma using a folate receptor α-targeted dual-modal nanoprobe